文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

羟氯喹对需氧疗的COVID-19肺炎患者的临床疗效:基于常规诊疗数据的观察性比较研究

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
PubMed 文献 · BMJ · 2020-05-14
一句话结论在需氧疗但未入ICU的COVID-19肺炎住院患者中,入院48小时内使用羟氯喹600 mg/日未改善第21天无ICU转归生存,作者认为结果不支持其使用。

这项法国四家三级中心2020年3月12日至31日的观察性比较研究纳入181例18-80岁、需氧疗但未入ICU的SARS-CoV-2肺炎住院患者,比较入院48小时内羟氯喹600 mg/日(治疗组84例)与未用羟氯喹的标准治疗(对照组89例),另8例在入院48小时后使用羟氯喹。采用逆概率治疗加权校正混杂后,第21天无ICU转归生存率治疗组76% vs 对照组75%(加权HR 0.9,95%CI 0.4-2.1),总生存89% vs 91%(1.2,0.4-3.3),无ARDS生存69% vs 74%(1.3,0.7-2.6),撤氧82% vs 76%(加权RR 1.1,95%CI 0.9-1.3),均未达统计学显著。治疗组8例(10%)出现需停药的ECG改变。作者结论认为结果不支持对需氧疗的COVID-19住院患者使用羟氯喹。

要点

  • 需氧疗但未入ICU的COVID-19肺炎住院患者中,入院48小时内羟氯喹600 mg/日组第21天无ICU转归生存76% vs 未用组75%(加权HR 0.9,95%CI 0.4-2.1),未达统计学显著。
  • 第21天总生存治疗组89% vs 对照组91%(加权HR 1.2,95%CI 0.4-3.3),无ARDS生存69% vs 74%(加权HR 1.3,95%CI 0.7-2.6),均未达统计学显著。
  • 第21天撤氧率治疗组82% vs 对照组76%(加权RR 1.1,95%CI 0.9-1.3),未达统计学显著。
  • 治疗组8例(10%)出现需停用羟氯喹的心电图改变。
  • 作者结论认为本研究结果不支持对需氧疗的COVID-19住院患者使用羟氯喹。

适用人群与场景

  • 18-80岁、有SARS-CoV-2肺炎记录、需氧疗但未入ICU的住院患者,来自2020年3月12日至31日法国四家三级中心。

处置流程与药物剂量

  • 治疗组在入院48小时内开始羟氯喹600 mg/日;对照组接受不含羟氯喹的标准治疗;另有8例在入院48小时后使用羟氯喹。

红旗征与不能漏的情况

  • 治疗组8例(10%)出现需停用羟氯喹的心电图改变。

研究设计与关键结果

  • 研究类型为基于常规诊疗数据的观察性比较研究,纳入181例需氧疗但未入ICU的COVID-19肺炎住院患者,来自法国四家三级中心,比较入院48小时内羟氯喹600 mg/日(84例)与未用羟氯喹标准治疗(89例),另8例在入院48小时后使用羟氯喹。
  • 主要终点第21天无ICU转归生存率:治疗组76% vs 对照组75%,加权HR 0.9(95%CI 0.4-2.1)。
  • 第21天总生存率:治疗组89% vs 对照组91%,加权HR 1.2(95%CI 0.4-3.3)。
  • 第21天无ARDS生存率:治疗组69% vs 对照组74%,加权HR 1.3(95%CI 0.7-2.6)。
  • 第21天撤氧率:治疗组82% vs 对照组76%,加权RR 1.1(95%CI 0.9-1.3)。
  • 治疗组8例(10%)出现需停用羟氯喹的心电图改变。
  • 分析采用逆概率治疗加权校正混杂因素。

证据类型、等级与局限

  • 证据类型:观察性比较研究,使用常规诊疗数据,采用逆概率治疗加权校正混杂。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,本研究结果不支持对需氧疗的COVID-19住院患者使用羟氯喹。
  • 治疗组8例(10%)出现需停用羟氯喹的心电图改变。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.

DESIGN: Comparative observational study using data collected from routine care.

SETTING: Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020.

PARTICIPANTS: 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care.

INTERVENTIONS: Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group).

MAIN OUTCOME MEASURES: The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting.

RESULTS: In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment.

CONCLUSIONS: Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020. PMID: 32409486. doi:10.1136/bmj.m1844

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。